Dr. Miver Erem Tokuş
NeurosurgeryVerified
- 24+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Brain Surgery
Resection of glioblastoma
Surgical resection of glioblastoma aims for maximal safe tumour removal while preserving critical neurological function. This comprehensive clinical guide explains craniotomy techniques, intraoperative 5-ALA fluorescence, awake cortical mapping, evidence-based survival expectations, hospital costs in Turkey compared with the UK and Europe, intensive care recovery milestones, potential surgical complications, and criteria for selecting an accredited neurosurgical centre.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Brain Surgery
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Resection of Glioblastoma
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Resection of glioblastoma: what the procedure involves
Resection of glioblastoma is an advanced microsurgical neurosurgical operation that involves opening the skull (a craniotomy) to remove as much high-grade astrocytoma (glioblastoma, IDH-wildtype, WHO grade 4) tissue as safely achievable. Glioblastoma is an aggressive, diffuse primary central nervous system malignancy that infiltrates surrounding brain parenchyma. The primary objective of surgery is cytoreduction: reducing mass effect, lowering raised intracranial pressure, and alleviating neurological deficits while preserving vital speech, motor, and cognitive faculties. This principle is clinically termed maximal safe resection. For patients and families navigating complex care pathways, comprehensive surgical planning is an essential component of specialised neurosurgery treatments in Turkey.
Because glioblastoma cells microscopically invade cerebral tissue beyond the visible tumour boundary, surgical resection alone is not curative. Instead, extensive cytoreduction serves as the critical initial pillar of comprehensive management, making subsequent adjuvant therapies—such as targeted radiotherapy and temozolomide chemotherapy—substantially more effective. Patients seeking resection of glioblastoma in Turkey travel to access tertiary neurosurgical centres equipped with frameless neuronavigation, intraoperative neurophysiological monitoring, and dedicated neuro-intensive care units. This guide details how the operation is performed, what clinical evidence confirms, what it costs compared with the UK, US and Germany, what recovery entails and how to assess hospital accreditation.
How is surgical resection of glioblastoma performed?
Modern surgical resection of glioblastoma relies on refined microsurgical tools and real-time intraoperative guidance to balance tumour clearance against functional preservation. The operation begins with a tailored craniotomy, in which a small section of cranial bone overlying the tumour trajectory is temporarily removed. Using computer-assisted neuronavigation calibrated to pre-operative high-resolution magnetic resonance imaging (MRI), the neurosurgeon maps the three-dimensional boundaries of the lesion with millimetre precision.
To distinguish malignant tumour margins from normal brain tissue, surgeons frequently administer 5-aminolevulinic acid (5-ALA), an oral contrast agent ingested several hours before surgery. Under a surgical microscope equipped with a violet-blue filter, glioblastoma tissue synthesises fluorescent porphyrins that glow vivid red or pink, revealing infiltrative margins that appear indistinguishable under conventional white illumination. The surgeon employs Cavitron Ultrasonic Surgical Aspirators (CUSA) to fragment and suck away tumour tissue while sparing adjacent blood vessels. Bipolar micro-electrocautery maintains strict haemostasis. In selected centres, intraoperative ultrasound or intraoperative MRI (iMRI) is utilised before closure to confirm whether additional tumour tissue can be safely excised. Once resection reaches predetermined functional limits, the dura mater is sutured watertight, the cranial bone flap is repositioned with titanium microplates, and the scalp is meticulously closed in anatomical layers.
Does surgical resection work for glioblastoma?
When evaluating whether surgical resection works, neuro-oncologists evaluate both immediate neurological symptom relief and long-term survival prolongation. Clinical evidence across neurosurgical oncology establishes that the extent of resection (EOR) directly influences patient outcomes. Landmark clinical trials demonstrate that achieving a gross total resection—defined as removing at least 98% of contrast-enhancing tumour volume on early post-operative MRI—is associated with significantly prolonged progression-free survival and extended median overall survival compared with partial debulking or biopsy alone.
Crucially, extensive tumour clearance must never compromise functional brain tissue. Surgically induced neurological deficits, such as motor paresis or expressive dysphasia, impair functional independence and delay or preclude the initiation of standard adjuvant chemoradiotherapy (the Stupp protocol). International neuro-oncology guidelines therefore emphasize maximal safe resection as the optimal balance. Surgery reliably resolves mass effect, controls intracranial hypertension, alleviates headaches, and reduces corticosteroid dependence. However, surgery cannot prevent microscopic recurrence at cellular margins; it provides an essential foundation for life-prolonging multimodal therapy rather than a standalone cure.
Resection of glioblastoma cost in Turkey compared with the UK, US and Germany
Neurosurgical oncology requires specialised operating theatre technology, advanced micro-instrumentation, neuro-anaesthesia, and intensive care monitoring. The approximate cost of resection of glioblastoma in Turkey is substantially lower than in Western Europe and North America, reflecting differences in institutional operating overheads and inclusive medical travel arrangements. The table below presents honest, approximate price ranges across international healthcare systems.
| Country | Approximate cost range |
|---|---|
| Turkey | €12,000 – €24,000 |
| United Kingdom | €28,000 – €55,000 |
| United States | €65,000 – €140,000 |
| Germany | €25,000 – €50,000 |
Several clinical variables determine the total resection of glioblastoma cost. Key factors include whether the tumour resides in eloquent cortex requiring awake craniotomy with intraoperative neuro-monitoring, the use of 5-ALA fluorescence or intraoperative MRI, the duration of stay in the neuro-intensive care unit (NICU), and the depth of histopathological and molecular profiling (including MGMT promoter methylation and IDH mutation testing). In Turkey, surgical packages typically incorporate pre-operative neuroimaging, surgical fees, anaesthesia, intraoperative consumables, two to three nights in neuro-intensive care, four to seven days in a private hospital ward, post-operative MRI, routine medications, and airport transfers. Patients are advised to obtain a detailed written breakdown before committing; you can request a customised assessment and free quote based on your recent diagnostic scans.
Surgical approaches: gross total resection, subtotal debulking and biopsy
The neurosurgical strategy is individualised according to tumour location, relationship to critical neural tracts, and patient performance status. While tumours located in non-eloquent areas (such as the right anterior frontal pole) may permit complete macroscopic clearance, tumours infiltrating speech or motor pathways require cautious subtotal resection. Note that unlike skull-base or pituitary conditions treated through an endoscopic transnasal resection of tumor, glioblastoma mandates a formal transcranial open craniotomy.
| Surgical approach | Clinical indication | Typical limits |
|---|---|---|
| Gross total resection (5-ALA guided) | Well-defined tumours in accessible, non-eloquent cortical lobes | Cannot clear microscopic non-enhancing cells infiltrating beyond contrast margins |
| Subtotal debulking with functional mapping | Tumours adjacent to or directly involving speech or motor pathways | Leaves residual enhancing tissue deliberately to preserve vital neurological faculties |
| Frameless stereotactic needle biopsy | Deep-seated thalamic, brainstem, or bi-hemispheric lesions | Provides tissue for molecular diagnosis only; does not alleviate tumour mass effect |
A neuro-oncology multidisciplinary tumour board evaluates pre-operative MRI tractography to determine the safest surgical pathway. When a tumour directly abuts expressive language centres (Broca's area) or the primary motor cortex, an awake craniotomy is conducted. Under mild sedation and local scalp anaesthesia, the patient communicates with a neuropsychologist and performs specific counting or object-naming tasks while the surgeon stimulates the cortex, ensuring that critical eloquent networks remain untouched throughout resection.
Who is an appropriate candidate for craniotomy and resection?
Surgical candidacy for major craniotomy is governed by strict clinical criteria designed to maximize survival gains while minimizing post-operative neurological deficits. Favourable candidates typically exhibit:
- A high functional baseline, defined by a Karnofsky Performance Scale (KPS) score of 70 or higher, reflecting independent self-care and physiological resilience.
- A unifocal, surgically accessible tumour identifiable on contrast-enhanced cranial MRI.
- Absence of uncompensated cardiopulmonary illness or irreversible systemic coagulopathy.
- Clinical suitability for subsequent adjuvant chemoradiotherapy following surgical recovery.
Conversely, aggressive open resection is generally unsuitable for patients presenting with deep bi-hemispheric butterfly tumours crossing the corpus callosum, direct brainstem infiltration, multifocal intracranial disease, or severe pre-existing physical or cognitive impairment (KPS below 50–60). In these clinical presentations, open craniotomy exposes the patient to substantial neurological risk without demonstrable survival benefit; a stereotactic needle biopsy followed by palliative or targeted radiotherapy is recommended instead.
The surgical journey: pre-operative mapping, anaesthesia and theatre steps
Undergoing craniotomy for resection of glioblastoma involves meticulous preparation across consecutive stages:
- Pre-operative evaluation and advanced imaging: Upon hospital admission, the patient undergoes volumetric 3D contrast-enhanced MRI, diffusion tensor tractography (DTI) to visualise white-matter tracts, and functional MRI (fMRI) if the lesion borders speech or motor cortex. Routine haematology, renal function, coagulation screens, and neuro-anaesthetic reviews are performed.
- Anaesthesia and patient positioning: General endotracheal anaesthesia is standard, utilizing short-acting intravenous agents to ensure prompt post-operative neurological assessment. For awake craniotomy, an asleep-awake-asleep protocol is carefully managed. The patient's head is stabilized in a rigid three-point Mayfield clamp linked to the neuronavigation tracking system.
- Craniotomy and dural opening: The scalp is incised along a tailored hairline marking, and a bone window is fashioned using a high-speed neurosurgical drill and craniotome. The dura mater is incised and reflected under magnification.
- Microsurgical tumour debulking: Utilising the operating microscope and 5-ALA fluorescence, the neurosurgeon works systematically from the tumour centre outward. Ultrasonic aspiration fragments and removes malignant tissue while continuous neurophysiological monitoring tracks sensory and motor pathways.
- Haemostasis and cranial reconstruction: Meticulous haemostasis is achieved using bipolar coagulation and topical haemostatic sealants. The dura is closed watertight, often augmented with a synthetic dural graft to prevent fluid leakage. The bone flap is secured with low-profile titanium plates, a subgaleal drain is placed if indicated, and the scalp is closed in layers with sutures or surgical staples. Surgery typically lasts between 4 and 7 hours.
Recovery milestones and your stay in Turkey
Post-operative recovery following glioblastoma surgery is intensive and closely monitored. Immediately after theatre, the patient is transferred to the neuro-intensive care unit (NICU) for continuous hemodynamic oversight, frequent neurological pupil and limb assessments, and management of cerebral perfusion pressure. Most patients remain in the NICU for 24 to 48 hours before transferring to a dedicated neurosurgical ward.
The standard progression for resection of glioblastoma recovery includes:
- Days 1 to 3: Initiation of assisted physical therapy, continuation of anti-seizure prophylaxis (such as levetiracetam), and steroid tapering with dexamethasone to control peri-tumoural oedema.
- Within 48 to 72 hours: A mandatory early contrast-enhanced MRI is performed. This specific post-operative window is crucial because surgical reactive enhancement has not yet formed, allowing accurate calculation of residual tumour volume.
- Days 4 to 7: Transition to independent mobility, wound inspection, and discharge from inpatient hospital care to local accommodation once stable.
- Days 8 to 14: Outpatient suture or staple removal, assessment of healing, and multidisciplinary discussion of the definitive histopathology and molecular genetics (including MGMT methylation and IDH status). International patients typically stay in Turkey for 10 to 14 days before being cleared for air travel.
Patients arranging medical travel should consult our detailed guide on how it works to ensure coordinated transfer of care between Turkish neurosurgeons and domestic oncology teams.
Neuroimaging and clinical outcomes: what to realistically expect
Unlike aesthetic surgeries that showcase external cosmetic changes, before-and-after assessments in neuro-oncology rely exclusively on comparative cross-sectional neuroimaging and objective neurological evaluations. Pre-operative scans typically show an irregular, thick ring-enhancing mass with central necrosis, surrounded by prominent vasogenic oedema that causes ventricular compression and midline brain shift. Effective post-operative imaging demonstrates the complete or near-complete disappearance of contrast-enhancing tissue, decompression of the ventricles, and restoration of midline anatomy.
Clinically, patients and families should maintain realistic expectations regarding functional outcomes:
- Symptom resolution: Successful cytoreduction rapidly alleviates elevated intracranial pressure, resolving severe morning headaches, nausea, and cognitive clouding.
- Transient neurological fluctuations: Surgical manipulation and temporary oedema around the resection margins can cause mild, transient worsening of motor strength, speech fluency, or balance during the first post-operative fortnight. These symptoms typically improve as inflammation subsides.
- The oncological timeline: Surgery creates a critical therapeutic window. It debulks the bulk of the malignancy and yields tumour tissue for molecular subtyping. Adjuvant radiotherapy and temozolomide chemotherapy generally commence four to six weeks following surgery, once cranial incisions have completely healed.
Risks and potential complications of intracranial surgery
Craniotomy for high-grade glioma is a major surgical procedure carrying recognized neurological and systemic risks. Recognized neurosurgical bodies—including the NHS, the European Association of Neuro-Oncology (EANO), and the Congress of Neurological Surgeons (CNS)—identify the following primary complications:
- Neurological deficits: Tumour resection near eloquent cortex carries a risk of post-operative motor weakness, sensory changes, visual field deficits, or speech impairment (dysphasia). While many deficits resolve with neuro-rehabilitation, some may be permanent.
- Intracranial haemorrhage: Post-operative bleeding into the resection bed or subdural space occurs in approximately 1% to 3% of cases and may require emergency surgical evacuation.
- Cerebral oedema: Reactive swelling around the operative cavity can raise intracranial pressure, requiring medical management with intravenous dexamethasone or hypertonic saline.
- Post-operative seizures: Cortical disruption can provoke epileptic activity; prophylactic anti-convulsant therapy is administered routinely to mitigate this risk.
- Cerebrospinal fluid (CSF) leak and infection: Imperfect dural closure can lead to CSF drainage through the wound or nasal passages, predisposing to meningitis or bone flap infection requiring antibiotic therapy or re-operation.
- Venous thromboembolism: Neurological patients face an elevated risk of deep vein thrombosis (DVT) and pulmonary embolism, managed via pneumatic calf compression and low-molecular-weight heparin once intracranial haemostasis is secure.
How to select a neurosurgical hospital and critical red flags
Undergoing brain tumour surgery abroad requires rigorous verification of institutional capabilities. When evaluating centres for resection of glioblastoma Turkey, prioritize hospitals meeting the following criteria:
- Subspecialist surgical credentials: The operating neurosurgeon should possess dedicated fellowship training in neuro-oncological surgery, with extensive documented experience in awake craniotomy and fluorescent-guided microsurgery.
- Advanced theatre technology: The surgical suite must feature frameless neuronavigation, intraoperative neurophysiological monitoring (IONM), surgical microscopes fitted with 5-ALA fluorescence filters, and on-site intraoperative imaging.
- Dedicated neuro-intensive care: An accredited neuro-ICU staffed 24/7 by specialist neuro-intensivists is essential for the management of acute post-operative intracranial dynamics.
- Multidisciplinary tumour board (MDT): Comprehensive care requires coordinated input from neurosurgeons, radiation oncologists, medical oncologists, and neuropathologists.
Red flags to watch for: Avoid facilities lacking dedicated neuro-intensive care beds, clinics quoting fixed costs without requesting and reviewing recent contrast-enhanced MRI scans, brokers who claim surgery provides a definitive cure, or surgeons who do not routinely utilise intraoperative monitoring or 5-ALA guidance.
Essential questions to ask your surgical team:
- What anticipated percentage of the contrast-enhancing tumour can be safely resected?
- Will 5-ALA fluorescence guidance and intraoperative neurophysiological monitoring be used during my surgery?
- What are the specific neurological risks given the anatomical location of my tumour?
- How many days will I be monitored within the specialized neuro-intensive care unit?
- How do you coordinate with my domestic medical team regarding tissue blocks, pathology reports, and molecular profiling?
To evaluate your treatment options, explore our complete directory of neurosurgery treatments in Turkey and submit your diagnostic scans for a comprehensive multidisciplinary review through our free quote portal.
Conditions treated with Resection of Glioblastoma
Hospitals with Neurosurgery in Turkey
Frequently asked questions
Resection of glioblastoma is an open microsurgical craniotomy performed to remove as much high-grade astrocytoma tumour tissue as safely possible. Using advanced neuronavigation, operating microscopes, and fluorescent dyes like 5-ALA, the neurosurgeon debulks the tumour to alleviate intracranial pressure, reduce mass effect, and prepare the patient for subsequent radiotherapy and chemotherapy.
No, surgical resection alone is not a cure for glioblastoma because malignant cells microscopically infiltrate normal brain tissue beyond the visible tumour margin. However, maximal safe resection significantly prolongs median survival, improves neurological symptoms, enhances overall quality of life, and makes follow-up chemoradiotherapy substantially more effective.
The approximate cost of resection of glioblastoma in Turkey ranges between €12,000 and €24,000, compared with €28,000 to €55,000 in the UK and significantly higher in the US. The price depends on tumour complexity, surgical duration, 5-ALA utilization, and the required length of stay in the neuro-intensive care unit.
Before-and-after assessments rely on contrast-enhanced cranial MRI rather than external photos. Pre-operative imaging reveals a contrast-enhancing mass with surrounding brain swelling and midline shift. Post-operative scans performed within 72 hours should demonstrate elimination of the enhancing tumour mass, relief of mass effect, and preserved normal cerebral architecture.
Initial hospital recovery typically lasts five to seven days, including one to two days in intensive care. Patients generally walk with assistance within forty-eight hours. Most international patients stay in Turkey for ten to fourteen days for wound review and molecular histology before returning home to begin adjuvant chemoradiotherapy after four to six weeks.
The brain itself has no pain receptors, and surgery is performed under deep general anaesthesia or carefully targeted local scalp blocks. Afterwards, patients feel scalp soreness, headache, and fatigue. These discomforts are closely monitored and managed with scheduled intravenous analgesics and anti-inflammatory medications during the hospital stay.
A craniotomy for resection of glioblastoma generally takes between four and seven hours. The duration depends on tumour size, anatomical depth, surgical vascularity, and whether advanced techniques—such as awake cortical mapping, intraoperative ultrasound, or intraoperative magnetic resonance imaging—are required to verify resection boundaries safely.
While intracranial surgery carries serious risks such as neurological deficit, bleeding, infection, and seizures, modern microsurgical techniques have significantly improved safety. Performing the operation in tertiary neurosurgical centres with intraoperative neurophysiological monitoring, neuronavigation, and dedicated neuro-intensive care keeps complication rates low while maximizing safe tumour clearance.
Not all glioblastomas are suitable for extensive resection. Tumours deeply embedded in critical brainstem structures, bi-hemispheric butterfly gliomas, or multifocal disease pose unacceptable risks of permanent neurological disability. In such cases, neurosurgeons recommend a stereotactic needle biopsy to obtain tissue for molecular analysis, followed by targeted non-surgical therapies.
Patients typically require a total stay of ten to fourteen days in Turkey. This comprises pre-operative cardiac and neuroimaging evaluations, five to seven days of inpatient hospital care (including neuro-ICU observation), early post-operative MRI, suture removal, and initial review of preliminary pathology before receiving medical clearance to fly.
Patient stories